Phase I study evaluating the combination of lapatinib + vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.

Trial Profile

Phase I study evaluating the combination of lapatinib + vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2014

At a glance

  • Drugs Lapatinib (Primary) ; Vinorelbine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jan 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 20 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top